Table 4.
Adverse Events
| Spironolactone (n=29) | Placebo (n=32) | |
|---|---|---|
| Dizziness/lightheadedness | 3 (10%) | 3 (9%) |
| Muscle cramping/soreness | 2 (7%) | 3 (9%) |
| Vision changes | 2 (7%) | 1 (3%) |
| Increased urination | 2 (7%) | 0 (0%) |
| Hyperkalemia | 0 (0%) | 1 (3%) |
| Fatigue | 1 (3%) | 1 (3%) |
| Increased thirst | 0 (0%) | 1 (3%) |
| Nausea | 0 (0%) | 1 (3%) |
| Mildly elevated AST/ALT | 0 (0%) | 1 (3%) |
Spironolactone groups includes n=1 participant who discontinued study participation due to inability to tolerate frequent urination.
ALT, alanine transaminase; aspartate aminotransferase, AST.